Early Discharge and Outpatient Care After Chemotherapy in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: Gathering information about patients with myelodysplastic syndrome or acute myeloid leukemia who are discharged after finishing chemotherapy, or who stay in the hospital until blood counts return to normal, may help doctors learn more about a patient's quality of life, use of medical services, and the cost of these services.
PURPOSE: This clinical trial is studying early discharge and outpatient care in patients who have undergone chemotherapy for myelodysplastic syndrome or acute myeloid leukemia.
| Condition | Intervention |
|---|---|
|
Leukemia Myelodysplastic Syndromes |
Other: medical chart review Other: questionnaire administration Procedure: quality-of-life assessment |
| Study Type: | Interventional |
| Study Design: | Primary Purpose: Health Services Research |
| Official Title: | Pilot Study of Feasibility, Safety, and Economics of Early Discharge and Outpatient Management of Adult Patients Following Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Non-APL Acute Myeloid Leukemia |
- Death rate in patients discharged after completion of induction chemotherapy [ Designated as safety issue: No ]
- Rate of successful discharge of patients who meet medical discharge criteria [ Designated as safety issue: No ]
- Costs associated with outpatient vs inpatient treatment [ Designated as safety issue: No ]
- Medical resources used with outpatient vs inpatient treatment [ Designated as safety issue: No ]
| Estimated Enrollment: | 96 |
| Study Start Date: | December 2008 |
| Study Completion Date: | March 2011 |
| Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
- To compare the death rate in patients with myelodysplastic syndromes or acute myeloid leukemia who are discharged after completion of induction chemotherapy vs those who remain in the hospital until blood counts recover.
Secondary
- To determine the proportion of patients who meet the early discharge criteria after completion of induction chemotherapy.
- To compare the costs incurred by patients who are discharged early vs those who are discharged only after blood counts recover.
- To compare resource utilization (e.g., transfusions) among these patients.
- To compare the quality of life of these patients.
OUTLINE: Within 72 hours after completion of induction chemotherapy, patients are either discharged from the hospital or remain in the hospital until their blood counts recover.
Patients receive standard supportive care after completion of induction chemotherapy either in the hospital or as an outpatient. Outpatients are seen by a registered nurse or physician assistant ≥ 3 times weekly and by a physician at least once weekly.
A medical chart review is conducted to obtain information about medical complications (e.g., neutropenic fever, documented infections, bleeding, reasons for hospitalization) and use of medical resources. Patients complete the MDA Symptom Inventory and the EORTC QLQ-C30 questionnaire periodically to assess quality of life. Costs associated with inpatient and outpatient care are evaluated using electronic billing information from the University of Washington Medical Center and Seattle Cancer Care Alliance.
After completion of the study, patients are followed up for 1 month.
Eligibility| Ages Eligible for Study: | 18 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of one of the following:
- Myelodysplastic syndromes
Acute myeloid leukemia (AML)
- No acute promyelocytic leukemia with t(15;17)(q22;q12), PML/RAR, or other variants
- Planning to undergo AML-like intensive induction chemotherapy (e.g., "7+3" or regimen with similar or higher intensity) for untreated or relapsed disease within 1 week after study entry OR has started therapy within the past 72 hours
PATIENT CHARACTERISTICS:
- No hypersensitivity or allergy to fluoroquinolones, triazoles, or acyclovir
- ECOG/WHO/ZUBROD performance status 0-1*
- Total bilirubin ≤ 2.5 times upper limit of normal (ULN) (unless elevation is thought to be due to Gilbert's syndrome or hemolysis)*
- AST and ALT ≤ 1.5 times ULN*
- Serum creatinine ≤ 1.5 times ULN*
- No clinical evidence of congestive heart failure*
- No active bleeding*
- Not refractory to platelet transfusions (e.g., due to HLA-alloimmunization)*
- No requirement for IV antimicrobial therapy*
- Agrees to undergo close follow-up that includes ≥ 3 visits per week at the Seattle Cancer Care Alliance (SCCA)*
- Has a confirmed reliable caregiver and transportation*
- Confirmed temporary or permanent residency within a 30-minute commute from the University of Washington (UW) Medical Center/SCCA*
- Has identified a UW/SCCA hematologist/oncologist who is willing to care for the patient in the outpatient clinic* NOTE: *Additional criteria for early discharge from the hospital
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations| United States, Oregon | |
| Oregon Health and Science University | |
| Portland, Oregon, United States, 97201-3098 | |
| United States, Washington | |
| Fred Hutchinson Cancer Research Center | |
| Seattle, Washington, United States, 98109-1024 | |
| Switzerland | |
| Clinical Cancer Research Center at University Hospital Basel | |
| Basel, Switzerland, CH-4031 | |
| Principal Investigator: | Roland Walter, MD, PhD | Fred Hutchinson Cancer Research Center |
More Information
Additional Information:
No publications provided by Fred Hutchinson Cancer Research Center
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Roland Walter, Fred Hutchinson Cancer Research Center |
| ClinicalTrials.gov Identifier: | NCT00844441 History of Changes |
| Other Study ID Numbers: | 2300.00, P30CA015704, FHCRC-2300.00, IR 6845, CDR0000631997 |
| Study First Received: | February 13, 2009 |
| Last Updated: | May 17, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Fred Hutchinson Cancer Research Center:
|
de novo myelodysplastic syndromes previously treated myelodysplastic syndromes secondary myelodysplastic syndromes recurrent adult acute myeloid leukemia untreated adult acute myeloid leukemia adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute minimally differentiated myeloid leukemia (M0) adult acute myeloblastic leukemia without maturation (M1) |
adult acute myeloblastic leukemia with maturation (M2) adult acute myelomonocytic leukemia (M4) adult acute monoblastic leukemia (M5a) adult acute eosinophilic leukemia adult acute monocytic leukemia (M5b) adult acute megakaryoblastic leukemia (M7) adult acute basophilic leukemia acute myeloid leukemia with multilineage dysplasia following myelodysplastic syndrome adult erythroleukemia (M6a) adult pure erythroid leukemia (M6b) |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Myeloid, Acute Leukemia, Myeloid Myelodysplastic Syndromes Preleukemia |
Neoplasms by Histologic Type Neoplasms Bone Marrow Diseases Hematologic Diseases Precancerous Conditions |
ClinicalTrials.gov processed this record on June 17, 2013